Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Ultra-high resolution and ultra-sensitive fluorescence methods for objective sub-cellular diagnosis of early disease and disease progression in breast and prostate cancer (FLUODIAMON)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Sweden,Germany,Germany,Germany,Germany,Finland,Netherlands,Ireland,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-06-01
End date: 2012-05-31
Duration (months): 48.0
Total project cost (EUR): 5542587.2
EU funding (EUR): 4197774.0
Participants: 12
Project status: CLOSED

The overall objective of this proposal is to develop and validate a quantitative, minimally invasive diagnostic tool for early and conclusive detection, diagnosis and monitoring of disease and disease progression of breast and prostate cancer. A methodology will be developed making use of a combination of the probably most exciting recent advances in the field of light microscopy, for fluorescence-based optical imaging of individual sample cells. It includes advances which will take the spatial resolution far beyond the fundamental limits of optical resolution, the sensitivity down to an ultimate single-molecule level, and multi-parameter detection schemes significantly increasing the fluorescence information by which these cellular images can be analysed. Apart from detecting and identifying tumour markers in the samples, tumour-specific spatio-temporal molecular distributions within the intact sample cells will be exploited. This is to date an almost unexploited dimension of diagnostic information. By combining and supporting these novel optical methods with state-of-the-art affinity molecule biotechnology, , tumor biomarkers, fluorophore chemistry, and bioinformatic validation tools, all possible means will be exploited to extract a maximum amount of information out of very small amounts of sample material. We thereby expect that an improved, early and reliable diagnosis of breast and prostate cancer will be possible, from amounts of sample material small enough that a minimally invasive procedure such as Fine-needle aspiration (FNA) can be used. In addition, by the minimally invasive FNA-based sampling, serious sampling-related side-effects, such as seeding and spread of cancer cells can be completely avoided. Given the high incidence of breast and prostate cancer, and the utmost importance of an early and conclusive diagnosis for the prognosis of these diseases, the relevance of this project can not be overestimated.

Keywords: fluorescence microscopy single molecule cancer diagnostics proteomics combinatorial library
European Network for Cell Imaging and Tracking Expertise (ENCITE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Austria,Netherlands,United Kingdom,Israel,Germany,Italy,Czechia,Germany,Belgium,France,Germany,Italy,Netherlands,Spain,Germany,Belgium,United Kingdom,Spain,Netherlands,Switzerland,Germany,Italy,Spain
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-06-01
End date: 2012-11-30
Duration (months): 54.0
Total project cost (EUR): 15503366.2
EU funding (EUR): 11997945.0
Participants: 30
Project status: CLOSED

Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an “active drug” 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and clinical studies, however, success rates have been variable and clinical benefits have been limited. A major issue is the fact that the mechanisms by which cell therapy works in the different disease areas, are still poorly understood. The ability to non-invasively monitor the fate and modes of action of transplanted cells over time is mandatory. The development of relevant imaging tools will lead to a better understanding of how cell therapy works, the possibility of response monitoring in patients, and sufficient safety of the treatment.. ENCITE will provide tools to allow this by developing; • New imaging methods to improve the spatio-temporal tracking of labelled cells • Dual- and multimodality imaging procedures to cross-validate each individual approach • New contrast agents and procedures that will improve the sensitivity and specificity of cellular labelling • Combining of molecular biology for the generation of molecular and cellular imaging reporters with multimodal imaging techniques • Novel cell and animal reporter systems detecting the location and function of individual cells and small cell subsets within the target organ • Cellular labelling that does not interfere with cellular functions and therapeutic efficacy • Methods for quantitative assessment to generate reliable biomarkers of the cell fate and therapeutic effects • Cell homing for therapeutic delivery to target organs The tools and methodologies developed will be validated in 5 key disease areas; Neurological, Cardiovascular, Musculoskeletal, Diabetes and Cancer.

Keywords: cellular labelling multimodality imaging tracking molecular biology reporter systems neurological cardiovascular musculoskeletal diabetes cancer
The role of mRNA-processing bodies in ageing (PAGE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Cellular and Developmental Biology
Countries involved: Greece
Call:  (ERC-2007-StG, 2007)
Start date: 2008-09-01
End date: 2014-08-31
Duration (months): 72.0
Total project cost (EUR): 1080000.0
EU funding (EUR): 1080000.0
Participants: 1
Project status: CLOSED

Recently, we and others have revealed that, in the nematode Caenorhabditis elegans, reduction of protein synthesis rates in somatic cells extends lifespan. Based on this, we postulate that the molecular factors and mechanisms that control the mRNA metabolism in post-mitotic cells are critical determinants of ageing. This project will validate this hypothesis using C. elegans as main model system, but parallel studies in Saccharomyces cerevisiae and Drosophila melanogaster will prove the conservation of our observations. The cellular factors involved in mRNA metabolism (degradation/storage) are localized at specific particles in the cytoplasm of all eukaryotic cells, termed mRNA processing (P) bodies. Additionally, stress granules are cytoplasmic sites of mRNA-metabolism that are formed under stress conditions in mammalian cells. The objectives of this project include: -Monitoring of both P bodies and stress granules in adult worms and characterization of the age-related alterations in their profile, by immunostaining and real-time fluorescence imaging -Direct alterations in the expression of genes encoding factors of each particle in wild-type worms and analysis of the effects on lifespan and stress resistance -Comparison of the age-related changes in the profile of P bodies and stress granules between wild-type and long- or short-lived mutant worms -Direct alterations in the expression of genes encoding factors of each particle in worms with altered lifespan and investigation of the effects on lifespan and stress resistance -Observation of the age-related alterations in the profile of P bodies in yeast and flies, both in wild-type and long-lived strains. The rationale for this project is to provide insight into the modulation of ageing and stress resistance at the level of mRNA metabolism, which is a yet unexplored field of the biology of ageing and global stress response.

Keywords: ceanorhabditis elegans,lifespan,mrna metabolism,stress granules,p bodies
Resolve Chronic Inflammation and Achieve Healthy Aging by Understanding Non-regenerative Repair (RESOLVE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Austria,Italy,Italy,Hungary,Poland,Israel,Belgium,United Kingdom,Germany,Spain,Spain
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2013-09-30
Duration (months): 66.0
Total project cost (EUR): 14173960.86
EU funding (EUR): 10689714.0
Participants: 14
Project status: CLOSED

RESOLVE has been outlined to better understand the regulatory networks that control the devel-opmental processes in organ repair and to identify mechanisms which cause the termination of regu-lar organ development leading to fibroproliferative wound healing. Fibroproliferative wound healing represents a major pathology in elderly people shifting regular organ development into progressive organ fibrosis with complete loss of organ function. Based on the identification of valuated molecu-lar targets of fibroproliferative repair, RESOLVE aims to create suitable treatment strategies to achieve healthy ageing in the elderly. In doing so, RESOLVE will create a significant impact on life quality of elderly people. RESOLVE’s outcomes will strengthen the competitiveness of European science and biotechnology industry and contribute to cost saving strategies in the health care sector. RESOLVE’s structured scientific approach combines as yet fragmented fields of research using model organisms which represent (a) different forms of wound healing, (b) different human diseases and (c) different genetic backgrounds, guaranteeing social and scientific relevance, modularity of re-search and the integration of existing biological knowledge, technical expertise and medical experi-ence. In addition, sequential generation of data during improvement or worsening ensures clinical relevance and leads to a stringent exploitation strategy. The sustainable outcomes of RESOLVE’s efforts will be: (A) the urgently needed diagnostic tool for fibroproliferative wound healing in various organs, (B) highly valuable transgenic animals offering test systems for fibroproliferative wound healing, and (C) a characterization of compounds capable of interfering with targets involved in fibroprolifera-tive repair.

Keywords: regenerative versus fibroproliferative wound healing,aging,targeting,diagnostic gene chip,transgenic models
Neurotransmitter Cys-loop receptors: structure, function and disease (NEUROCYPRES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Belgium,Germany,United Kingdom,Austria,France,Russian Federation,Germany,United Kingdom,Switzerland,Italy,Greece,Germany,Germany,Sweden
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-02-01
End date: 2012-07-31
Duration (months): 54.0
Total project cost (EUR): 14640209.2
EU funding (EUR): 11025000.0
Participants: 24
Project status: CLOSED

Cys-loop receptors (CLRs) form a superfamily of structurally related neurotransmitter-gated ion channels, comprising nicotinic acetylcholine, glycine, GABA-A/C and serotonin (5HT3) receptors, crucial to function of the peripheral and central nervous system. CLRs cover a wide spectrum of functions, ranging from muscle contraction to cognitive functions. CLR (mal)function is linked to various disorders, including muscular dystrophies, neurodegenerative diseases, e.g. Alzheimer’s and Parkinson’s, and neuropsychiatric diseases, e.g. schizophrenia, epilepsy and addiction. CLRs are potentially important drug targets for treatment of disease. However, novel drug discovery strategies call for in depth understanding of ligand binding sites, the structure-function relationships of these receptors and insight into their actions in the nervous system. NeuroCypres assembles the expertise of leading European laboratories to provide a technology workflow, which enables to embark on this next step in CLR structure and function. A major target of this project is to obtain high-resolution X-ray and NMR structures for CLRs and their complexes with diverse ligands, agonists/antagonists, channel blockers and modulators, which will reveal basic mechanisms of receptor functioning from ligand binding to gating and open new avenues to rational drug design. In addition, the project aims at understanding receptor function in the context of the brain, focusing on receptor biosensors, receptor-protein interactions and transgenic models. This major challenge requires application and development of a multidisciplinary workflow of high-throughput (HT) crystallization and HT-electrophysiology technologies, X-ray analysis, NMR and computational modeling, fragment-based drug design, innovative quantitative methods of interaction-proteomics, sensitive methods for visualization of activity and localization of receptors and studies of in vitro and in vivo function in animal models of disease.

Keywords: cys-loop receptors,ion channels,structure,high-throughput analysis,nervous system,drug design
A new platform for fast molecular detection of MDR and XDR resistant strains of M. tuberculosis and of drug resistant malaria (TM-REST)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Germany,Bulgaria,Albania,United Kingdom,Switzerland,United Kingdom
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-06-30
Duration (months): 42.0
Total project cost (EUR): 4072768.2
EU funding (EUR): 2983207.0
Participants: 9
Project status: CLOSED

Recent developments in molecular tools combined with updated epidemiological data provide novel challenges to the development of modern molecular diagnostics. The increasing threat of infections due to Mycobacterium tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections poses important questions that call for development of integrated tools for rapid diagnosis. In the specific case of tuberculosis (TB), an integrated rapid diagnostic approach should be able to allow at the same time species identification, drug susceptibility testing and molecular typing. We propose to develop and validate a silicon-based platform for molecular biology testing consisting in a single disposable device (biochip) and on associated specific instruments (reader). This technology is able to simultaneously serve as a platform for high specificity amplification and hybridisation of selected targets, and to provide the diagnostic report within few hours. Main advancement over existing technology (i.e. Real-Time PCR) consists in the possibility to perform the test at competitive costs, using an higher number of genetic probes by integrating multiple, separate PCR chambers and medium density array (50-200 probes), with faster and more stable amplification and hybridisation reactions through optimised and controlled thermal ramps and profile. In addition to the technology development, special focus will be put on the feasibility and cost-effectiveness of such a novel tool with high technological content for application in countries with high TB, MDR- and XDR-TB incidence. In parallel to the development and validation of the chip-based diagnostic platform for TB, a feasibility study on its applicability to other poverty related diseases such as malaria, will be carried out. In summary, the present proposal aims at developing an affordable, high-tech platform for rapid molecular diagnosis applicable to TB and other infectious and poverty-related diseases

Keywords: mdr-tb,xdr-tb,fast molecular diagnosis,biochips
European Stroke Research Network (EUSTROKE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Sweden,Germany,United Kingdom,Germany,Switzerland,France,France,Italy,Germany,Hungary,Spain,Netherlands,Germany,Finland,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2013-08-31
Duration (months): 66.0
Total project cost (EUR): 13005201.6
EU funding (EUR): 9953915.0
Participants: 17
Project status: CLOSED

The European Stroke Research Network (EUSTROKE) will be a collaborative effort that brings together researchers, government, industry, the non-profit sector and patient group associations. This network will put Europe at the forefront of stroke research through its multi-disciplinary research program, high-quality training for European scientists and clinicians, and national and global partnerships. A primary focus of the EUSTROKE research programme is to improve our understanding of the neurovascular unit to enable better prevention and treatment of stroke. This involves elucidation of dynamic interactions of vascular, cellular and matrix signalling in both the grey and white matter of the brain. Our research strategy looks beyond the single cell for a more integrative answer to ischemic brain damage. The goals of EUSTROKE will be addressed by a wide variety of multidisciplinary European research teams working on various aspects of the neurovascular unit. Thus EUSTROKE will promote integration of both clinical and experimental research teams in cerebrovascular biology, imaging, prevention, and reperfusion with a common focus upon the NVU. The project will aim at developing new approaches for targeting the NVU to improve potential combination or multi-targeted treatments for stroke. Combination therapies that target the entire neurovascular unit, promote cell survival mechanisms and extend the therapeutic time-window for reperfusion therapy will provide new opportunities to meet the challenges of stroke. Moreover, developing therapies that maintain proper NVU function or prevent age-associated alterations in the NVU may find use in the prevention or treatment of cerebrovascular disease. Thus, the collaborative project will integrate its vast multidisciplinary capacities to generate new hypotheses and conduct exploratory work on microvessel–neuron communication.

Keywords: stroke,prevention,angiogenesis,neurovascular unit
European IPF Network: Natural course, Pathomechanisms and Novel Treatment Options in Idiopathic Pulmonary Fibrosis (EURIPFNET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Italy,France,Germany,Austria,Germany,Germany,Germany,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-06-30
Duration (months): 42.0
Total project cost (EUR): 3932864.2
EU funding (EUR): 2998589.0
Participants: 12
Project status: CLOSED

In the eurIPFnet consortium, leading European basic and clinical scientists in the field of interstitial lung diseases associate to jointly decipher the natural course and molecular pathomechanisms of Idiopathic Pulmonary Fibrosis (IPF) and to develop new therapeutic strategies for patients with IPF. This devastating disease affects about 360.000 patients in the EU and causes a substantial socioeconomic burden. IPF patients experience a gradual decrease in quality of life due to progressive dyspnoe and coughing, and usually die within 3-5 years upon diagnosis. There is currently no approved treatment available. Our translational research programme includes implementation of a European IPF registry (eurIPFreg), in which data with regard to natural course, familiar background and susceptibility factors of IPF will be collected, and of a European IPF biobank (eurIPFbank) of blood, bronchoalveolar lavage fluid, cells and tissue specimen of IPF. In these samples, we will perform transcriptome, proteome, phosphoproteome and lipidome analysis, cellular studies and genetic analysis to unravel the molecular pathways underlying IPF and to identify and establish new diagnostic and prognostic markers. Candidate gene verification will be performed in cell culture and animal studies, including siRNA and gene transfection technologies and development of genetically altered mice and will result in the development of new animal models of IPF. Identification of new therapeutic targets in these models will be followed by rapid commercial exploitation and early preclinical and early clinical evaluation. Ultimately, we wish to establish a unique, sustainable and internationally unrivalled European infrastructure for investigation and treatment of IPF. Our mission statement is straight-forward and clear: “Fighting for improved survival in Idiopathic Pulmonary Fibrosis”.

Keywords: idiopathic pulmonary fibrosis
The European Spallation Neutron Source (ESS) (NEUTRONSOURCEESS)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to new research infrastructures
Action type: Combination of CP & CSA
Countries involved: Switzerland,Spain,Sweden,United Kingdom,United Kingdom,Germany,Italy,France,Latvia,Hungary
Call:  (FP7-INFRASTRUCTURES-2007-1, 2007)
Start date: 2008-04-01
End date: 2010-03-31
Duration (months): 24.0
Total project cost (EUR): 6612468.33
EU funding (EUR): 4999995.5
Participants: 11
Project status: CLOSED

The European Spallation neutron Source (ESS) will be the world’s most powerful source of neutrons. Its design parameters makes it the most cost-effective top tier source for 40 years or more. A genuine pan‑European facility, it will serve a user community of 5,000 users annually across many areas of science and technology. Neutron beams produced by reactors are inherently intensity-limited. The ESS R&amp;D and design phase (&gt;50 M€; all major European labs, &gt;100 top scientists) has shown the feasibility of MW spallation sources. In line with the global neutron strategy endorsed by OECD ministers in 1999, the US has now commissioned its facility, based on an early ESS design, and Japan will follow suit in 2008. The initial long pulse configuration of ESS provides substantially higher power, maximum complementarity and the largest instrument innovation potential. Its technical layout guarantees a long-term top position. ESS will also offer new modes of operation and user support to maximally facilitate industry, in addition to university and research lab users. At present, two official bids for siting with a financial contribution in excess of 320M€ have been made by Spain (Bilbao) and Sweden (Lund). Hungary is expected to come forward with a similar bid soon. From the technical side the ESS is mature and detailed construction design work could start immediately after a positive decision has been taken. The cost issue (WP5) was very carefully assessed in the past and only needs final updating and inclusion of the decommissioning costs. Strategic, legal and governance issues have been investigated by the several possible sites. This information will be updated and collated (WPs 4,6,7). WP 8 will deal with Health, Safety and Environmental questions arising from possible different target materials (WP 9). WPs 1 and 2 concerns the management and the coordination of the project, respectively, and WP 3 the project assessment by an external Advisory Committee.

Keywords: neutron source,ess,spallation source,user facility